Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
22:40:09 EDT Fri 03 May 2024
Enter Symbol
or Name
USA
CA



Q:SMMT - SUMMIT THERAPEUTICS INC - https://www.summitplc.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
SMMT - Q1.14.19·4.413.04.39+0.338.11,862.67,7506,9124.08  4.50  4.065.22  1.5018:47:37May 0115 min RT 2¢

Recent Trades - Last 10 of 6912
Time ETExPriceChangeVolume
18:47:37Q4.410.3510
18:18:20Q4.400.34100
16:20:00Q4.390.331,788
16:00:05Q4.390.33200
16:00:00Q4.390.331,498
16:00:00Q4.390.334,872
16:00:00Q4.390.33223
16:00:00Q4.390.331,953
16:00:00Q4.390.334,700
16:00:00Q4.390.335,727

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-05-01 07:00U:SMMTNews ReleaseSummit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024
2024-04-24 16:30U:SMMTNews ReleaseSummit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024
2024-04-11 16:30U:SMMTNews ReleaseSummit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors
2024-04-10 07:00U:SMMTNews ReleaseSummit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum
2024-03-22 07:00U:SMMTNews ReleasePromising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024
2024-03-14 07:00U:SMMTNews ReleaseIntracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024
2024-03-05 07:00U:SMMTNews ReleaseSummit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
2024-02-20 07:00U:SMMTNews ReleaseSummit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023
2024-02-14 07:00U:SMMTNews ReleaseSummit Therapeutics to Host Fourth Quarter & Full Year 2023
2024-02-07 07:00U:SMMTNews ReleaseSummit Therapeutics to Present at Oppenheimer ¢ € ™s 34th Annual Healthcare Life Sciences Conference
2024-01-08 09:00U:SMMTNews ReleaseSummit Therapeutics Announces Updated Phase II Data for Ivonescimab at 42nd Annual J.P. Morgan Healthcare Conference
2024-01-03 07:30U:SMMTNews ReleaseSummit Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-11-07 07:00U:SMMTNews ReleaseSummit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023
2023-11-02 16:41U:SMMTNews ReleaseLaura Chow, MD, Cancer Immunotherapy Trailblazer, Joins Summit as Senior Vice President of Clinical Development
2023-10-31 08:00U:SMMTNews ReleaseIvonescimab ¢ € ™s Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023
2023-10-26 08:00U:SMMTNews ReleaseSummit Therapeutics to Host Q3 2023 Financial Results & Operational Progress Call on November 7, 2023
2023-10-19 08:00U:SMMTNews ReleaseH. Jack West, MD, Renowned Oncologist & Lung Cancer Expert, Joins Summit Therapeutics as Vice President of Clinical Development
2023-10-16 07:00U:SMMTNews ReleaseSummit Therapeutics Appoints Proven Biotech Leader Manmeet S. Soni as Chief Operating Officer
2023-08-09 07:00U:SMMTNews ReleaseSummit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2023
2023-08-02 08:00U:SMMTNews ReleaseSummit Therapeutics to Host Q2 2023 Financial Results & Operational Progress Call on August 9, 2023